Ophthalmology Times Newsletter

To view this email as a web page, click here.

LHON gene therapy: Deciphering phase III data

Phase III studies of a gene therapy for Leber hereditary optic neuropathy have generated some unexpected positive findings. There is biologic plausibility to explain the data, according to Robert C. Sergott, MD.

Continue

Flying solo poses challenges, flexibility and support vital

Ophthalmologists operating a small practice are looking for better patient relationships and independence, according to Lisa M. Nijm, MD, JD.

Learn more

Ophthalmology grabs Wall Street’s attention

Josh Mali, MD, shares how AbbVie’s recent financial takeover rattles up the ophthalmic space, and what this means for future pharmaceutical acquisitions.

Find out

Set expectations for glaucoma patients undergoing cataract surgery

(VIDEO) OSPREY trial aids fluid assessment

Photoreceptor replacement cells enter therapeutic space

Treating chalazion with IPL therapy

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.